Checkpoint Capital’s Trevi Therapeutics TRVI Stock Holding History

Checkpoint Capital’s Portfolio TRVI Stock Details TRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$597K	Buy	+50,000	New	+$560K	0.21%	8
2025 Q1	–	Sell	-1,084,135	Closed	-$4.47M	–	20
2024 Q4	$4.47M	Buy	1,084,135 +834,135	+334%	+$2.67M	2.27%	11
2024 Q3	$835K	Sell	250,000 -250,089	-50%	-$743K	0.41%	15
2024 Q2	$1.49M	Sell	500,089 -5,993	-1%	-$16.7K	0.9%	13
2024 Q1	$1.75M	Sell	506,082 -786,234	-61%	-$1.75M	1.17%	14
2023 Q4	$1.73M	Buy	+1,292,316	New	+$1.96M	1.05%	14

Other funds holding TRVI

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Checkpoint Capital's TRVI Position: Q1 2026 in Review

Checkpoint Capital opened a new position in Trevi Therapeutics (TRVI) in Q1 2026: 50,000 shares worth $597K. The stake represents 0.21% of the portfolio and ranks #8 among its holdings. This is a return to the name: Checkpoint Capital previously reported a position in TRVI as recently as Q4 2024.

Checkpoint Capital first reported a position in TRVI in Q4 2023 and has held it in 6 quarters since. The position peaked at $4.47M in Q4 2024. 198 funds tracked by Wall St. Rank hold TRVI as of Q1 2026.

Checkpoint Capital held 50,000 shares of Trevi Therapeutics worth $597K as of Q1 2026.
Trevi Therapeutics was a new Checkpoint Capital position in Q1 2026.
Trevi Therapeutics made up 0.21% of Checkpoint Capital's portfolio in Q1 2026, its #8 holding.
Checkpoint Capital first reported a position in Trevi Therapeutics in Q4 2023 and has held it in 6 quarters since.
Checkpoint Capital's Trevi Therapeutics position peaked at $4.47M in Q4 2024.
198 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q1 2026.

Based on Checkpoint Capital's 13F filing for Q1 2026, filed 15 May 2026.